Scott Thomas Jackson
CIK 1566617 · Chief Executive Officer · last filed 2026-05-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$272.2K
Companies
5
Total Filings
40
Lifetime Open-Market Net
$57.6K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MGNX | Director | 14,750 | $3.96 | $58.4K | $0 | 12 | 2026-05-20 |
| MURAV | Director | — | — | — | $0 | 5 | 2025-12-05 |
| SPRO | Director | 75,000 | $2.85 | $213.8K | $0 | 7 | 2025-06-16 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | 5,250 | $15.70 | $82.4K | $0 | 7 | 2024-05-01 |
| Celator Pharmaceuticals Inc (CPXX) Delisted | Chief Executive Officer | 0 | — | — | $57.6K | 8 | 2016-07-12 |
Recent Filings · Page 2 of 4
40 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-01 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-18 | MURAV | Grant (A) | — | $0 | EDGAR |
| 2023-10-10 | SPRO | Grant (A) | +20,000 | $0 | EDGAR |
| 2023-06-02 | MGNX | Grant (A) | — | $0 | EDGAR |
| 2023-05-22 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-09-19 | SPRO | Grant (A) | +15,000 | $0 | EDGAR |
| 2022-05-23 | MGNX | Grant (A) | — | $0 | EDGAR |
| 2022-05-20 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-08-18 | SPRO | Grant (A) | — | $0 | EDGAR |
| 2021-05-27 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +5,250 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.